CYTK - サイトキネティクス (Cytokinetics Incorporated)

CYTKのニュース

   Cytokinetics opens enrollment for late-stage reldesemtiv ALS study  2021/08/02 11:58:14 Seeking Alpha
   Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis  2021/08/02 11:30:00 Intrado Digital Media
Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Decline of SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo
   Hypertrophic Cardiomyopathy (HCM) Market Research Report 2021-2030: Major Players Include Mavacamten (Bristol Myers Squibb), CK-274 (Cytokinetics), and LCZ696 (Novartis)  2021/07/26 14:45:00 Business Insider Markets
DUBLIN, July 26, 2021 /PRNewswire/ -- The
   Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares  2021/07/23 16:45:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $27.50 per share. This includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, were approximately $316.25 million.
   Cytokinetics to Announce Second Quarter Results on August 5, 2021  2021/07/22 20:00:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the companys outlook for the future.
   Astellas Walks Away From $450M Research & Discovery Partnership With Cytokinetics  2021/05/03 18:48:46 Benzinga
Cytokinetics Inc (NASDAQ: CYTK ) revealed in an SEC filing that Astellas Pharma Inc (OTCMKTS: ALPMY) is walking away from a pact to research and develop skeletal sarcomere activators for diseases associated with muscle weakness. Astellas had extended the research pact initially set to expire on December 31 last year, through March of this year. But last week, Astellas gave written notice that it wants out of the pact altogether and gives up “all licenses and other rights” granted through the … Full story available on Benzinga.com
   Mizuho Securities Stick to Their Buy Rating for Cytokinetics By Investing.com  2021/04/13 08:15:01 Investing.com
Mizuho Securities Stick to Their Buy Rating for Cytokinetics
   Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 10,000 Shares of Stock  2021/03/19 23:32:53 Watchlist News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director L Patrick Gage sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 19th. The stock was sold at an average price of $24.45, for a total transaction of $244,500.00. Following the sale, the director now directly owns 31,762 shares in the company, valued at approximately […]
   Cytokinetics to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference  2021/01/06 21:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President…
   Morgan Stanley Stick to Their Buy Rating for Cytokinetics  2020/12/16 20:35:38 Investing.com
Morgan Stanley Stick to Their Buy Rating for Cytokinetics

calendar